Treatment with probiotics in experimental oral colonization by <i>Candida albicans</i> in murine model (DBA/2)

Matsubara, Victor Haruo; Silva, Eriques Gonçalves; Paula, Claudete Rodrigues; Ishikawa, Kenzo; Nakamae, Atlas Edson Moleros

doi:10.1111/j.1601-0825.2011.01868.x

Cited by 49 publications

(54 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been reported by Matsubara et al 40 who evaluated oral colonization with C. albicans in immunocompromised mice. Candida counts were significantly reduced in the groups treated with probiotic bacteria (L. acidophilus and L. rhamnosus) compared to untreated animals.…”

Section: Discussionsupporting

confidence: 89%

Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella

et al. 2015

View full text Add to dashboard Cite

(2015) Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C.albicans and attenuates the experimental candidiasis in Galleriamellonella, Virulence, 6:1, 29-39, DOI: 10.4161/21505594.2014 Probiotic strains of Lactobacillus have been studied for their inhibitory effects on Candida albicans. However, few studies have investigated the effect of these strains on biofilm formation, filamentation and C. albicans infection. The objective of this study was to evaluate the influence of Lactobacillus acidophilus ATCC 4356 on C. albicans ATCC 18804 using in vitro and in vivo models. In vitro analysis evaluated the effects of L. acidophilus on the biofilm formation and on the capacity of C. albicans filamentation. For in vivo study, Galleria mellonella was used as an infection model to evaluate the effects of L. acidophilus on candidiasis by survival analysis, quantification of C. albicans CFU/mL, and histological analysis. The direct effects of L. acidophilus cells on C. albicans, as well as the indirect effects using only a Lactobacillus culture filtrate, were evaluated in both tests. The in vitro results showed that both L. acidophilus cells and filtrate were able to inhibit C. albicans biofilm formation and filamentation. In the in vivo study, injection of L. acidophilus into G. mellonella larvae infected with C. albicans increased the survival of these animals. Furthermore, the number of C. albicans CFU/mL recovered from the larval hemolymph was lower in the group inoculated with L. acidophilus compared to the control group. In conclusion, L. acidophilus ATCC 4356 inhibited in vitro biofilm formation by C. albicans and protected G. mellonella against experimental candidiasis in vivo.

show abstract

Section: Discussionsupporting

confidence: 89%

Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Interestingly, the overall responses to nystatin were similar in both models and compared similarly to the reduction observed in other recent studies using oral administration of nystatin in mouse models (44,45); however, the HDP mimetic response appeared to be greater in the steroid-free model. This increased response could be due to improved activity of the mimetics at lower tissue burdens, not evident with nystatin, or to potential activation of the immune system by the HDP mimetic that helped clear the infection.…”

Section: Figsupporting

confidence: 83%

Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis

Ryan

Freeman

Masso-Silva

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

There is a strong need for new broadly active antifungal agents for the treatment of oral candidiasis that not only are active against many species of Candida, including drug-resistant strains, but also evade microbial countermeasures which may lead to resistance. Host defense peptides (HDPs) can provide a foundation for the development of such agents. Toward this end, we have developed fully synthetic, small-molecule, nonpeptide mimetics of the HDPs that improve safety and other pharmaceutical properties. Here we describe the identification of several HDP mimetics that are broadly active against C. albicans and other species of Candida, rapidly fungicidal, and active against yeast and hyphal cultures and that exhibit low cytotoxicity for mammalian cells. Importantly, specificity for Candida over commensal bacteria was also evident, thereby minimizing potential damage to the endogenous microbiome which otherwise could favor fungal overgrowth. Three compounds were tested as topical agents in two different mouse models of oral candidiasis and were found to be highly active. Following single-dose administrations, total Candida burdens in tongues of infected animals were reduced up to three logs. These studies highlight the potential of HDP mimetics as a new tool in the antifungal arsenal for the treatment of oral candidiasis.

show abstract

“…In the treatment of mycotic diseases, detailed in vitro and in vivo studies are needed to specify the extent of their effectiveness. Furthermore, viewpoints of the most recent data [79, 80] on oral and vaginal candidiasis therapy explored the treatment with probiotic bacteria that may be an effective alternative to prevent it. In this context, further studies are needed to evaluate the promising colonization results of these studies.…”

Section: Discussionmentioning

confidence: 99%

Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development

Bondaryk¹,

Kurzątkowski²,

Staniszewska³

2013

pdia

View full text Add to dashboard Cite

Recent progress in medical sciences and therapy resulted in an increased number of immunocompromised individuals. Candida albicans is the leading opportunistic fungal pathogen causing infections in humans, ranging from superficial mucosal lesions to disseminated or bloodstream candidiasis. Superficial candidiasis not always presents a risk to the life of the infected host, however it significantly lowers the quality of life. Superficial Candida infections are difficult to treat and their frequency of occurrence is currently rising. To implement successful treatment doctors should be up to date with better understanding of C. albicans resistance mechanisms. Despite high frequency of Candida infections there is a limited number of antimycotics available for therapy. This review focuses on current understanding of the mode of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of superficial and mucosal candidiasis.

show abstract

Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2)

Cited by 49 publications

References 24 publications

Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella

Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella

Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis

Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development

Contact Info

Product

Resources

About